WP5: Creating Impact

The uptake of the developed protocols and reference materials candidates, and alignment with industry beyond the consortium will be promoted through early engagement with additional industrial end users belonging to (i) the pharmaceutical industry and the medical device industry, (ii) SMEs that are members of the main European nanomedicine associations and (ii) instrument providers.

Importantly, the ETPN (European Nanomedicine Technology Platform) will lead the impact work package, addressing the whole European nanomedicine community, and benefitting from its well established network and methodology for community building and common strategic thinking.

Uptake of project outputs by private & public sector

End users:

1. Pharmaceutical industry, SMEs, analytical charcterisation laboratories and service providers (CROs),
2. Accademic experts
3. Regulatory agencies
4. EU projects in nanomedicine and Open Innovation Test Beds for nanopharmaceuticals and Medical devices

Outcomes:

1. Training courses and workshops on good laboratory practices
2. Webminars and workshops on standardisation activities in the field of nanomedicine
3. Exploitation of SOPs
4. B-testing (Demonstration) of validated protocols to industrial stakeholders

Tangible influence standards & regulation

1. New draft standards & technical specifications and partecipation to ongoing projects in multiple standardisation comites, including, the EDQM nanomedicine WG, ASTM E56.02 and ASTM E56.08, ISO TC 229, CEN TC 352, BIPM CCQM IAWG ‘Working Group on Inorganic Analysis, OECD WNT/WPMN ‘Expert Group on physical-chemical properties of nanomaterials’, ISO TC24 SC4 ‘Particle Characterization’, ISO/TC 201 ‘Surface chemical analysis’,
2. Roadmap for the commercialisation of 3 new reference materials selected during the project
3. Initiation of an external ILC study under VAMAS TWA 40 – Synthetic Biomaterials, focused on the results obtained by WP4

WP5 Leader:

Dr. Alexandre Ceccaldi
General Secretary –ETPN

Short bio: Alexandre Ceccaldi, General Secretary of the European Technology Platform on Nanomedicine (ETPN), holds a PhD in Biology from University Pierre and Marie Curie in Paris, and an engineering degree from Agro ParisTech. His expertise spans anticancer strategies, industrial management, and innovative design. He previously managed INGESTEM, a French consortium for induced pluripotent stem cell research. Since 2015, he has managed the ETPN Association, uniting 120 member institutions across Europe, representing all stakeholders from academia to large industry. He has coordinated the H2020 NOBEL Project and helped to establish the pioneering HealthTech4EU Alliance, acting for the convergence of all emerging health technologies in Europe. In 2023, he joined the Strategic Advisory Board of the ERA4HEalth funding programme